CHAMPION AF is the first large randomized trial comparing left atrial appendage (LAA) closure with DOAC therapy in patients eligible for anticoagulation.
The trial met its primary endpoints — but interpretation is key.
In this video, Prof. Horst Sievert provides a balanced and clinically relevant interpretation of the CHAMPION AF results, including:
– Non-inferiority vs DOAC therapy
– The stroke signal (key limitation)
– The bleeding trade-off (procedural vs long-term risk)
– The importance of patient selection
– Implications for real-world practice
Importantly, this is not about replacing DOAC therapy — it is about expanding treatment strategies.
Related content: https://www.csi-congress.org/laa